BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Bioxodes Raises EUR 2.6 Million (USD 3.5 Million) To Develop Antithrombotic Peptide Derived From Tick's Saliva


11/26/2013 7:32:41 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Marche-en-Famenne, Belgium, November 26, 2013 – Bioxodes SA, a company developing products derived from natural sources, has completed a EUR 2.6 million (USD 3.5 million) first seed funding round with a consortium of business angels and Belgian investment funds. EUR 1.6 million is from the European Regional Development Fund (ERDF) and the Walloon Region in Belgium via the Retech program for Research and Technology. It will be used to bring the company’s lead product Ir-CPI into pre-clinical development over the next 18 months.

Bioxodes, led by its founding CEO and chief scientific officer, Professor Edmond Godfroid, is exploiting the results of work conducted by his former team at the Ectoparasite Molecular Biology Unit at the University of Brussels (ULB), which focused on establishing the molecular basis of host-parasite relationships. Prior to the financing, Bioxodes had completed discussions with the ULB for the transfer of full ownership of patents relevant to Ir-CPI.

Ir-CPI is an antithrombotic derived from tick’s saliva, with the unprecedented property of inhibiting clotting at doses which do not cause bleeding. Thanks to a novel mechanism, Ir-CPI is potentially the world’s first injectable antithrombotic for use in all patient groups without causing high levels of bleeding. There is also potential to eliminate reversal or ‘washing out’ at the end of critical procedures. The market for an injectable form of such a molecule for use in hospitals is estimated to exceed USD 1 billion annually. According to Visiongain, the world antithrombotic drug market will reach revenue of USD 24.3 billion in 2015.

Ticks rank second only to mosquitoes as global vectors of disease. Research conducted in Prof. Godfroid’s laboratory has established the molecular basis of the parasitic relationship that a tick establishes with its vertebrate host. The particular tick studied is known as Ixodes ricinus, familiar to some as the carrier of Lyme disease. Ixodes ricinus is considered capable of infesting most terrestrial vertebrates in Europe.

Following a bite the tick feeds on the blood of its host. A particular characteristic of this feeding is its extended duration of up to two weeks. This long feeding involves no pain, blood clotting or inflammation. Scientists believe that such effects result from the presence of active principles in the saliva of the tick.

Professor Godfroid’s work has been instrumental in bringing Ir-CPI to a stage where it can enter full pre-clinical development. “We announced a year ago that we would initiate a fundraising drive. I am delighted that our company has been able to secure the necessary finance to allow us to conduct a program of pre-clinical testing for this promising molecule,” said Professor Godfroid. “We are also very pleased to have secured full ownership of the Ir-CPI patent portfolio arising from the original work in my laboratory.”

About Biodoxes - http://www.bioxodes.com

Bioxodes develops products derived from natural sources. The company controls intellectual property relating to these active molecules and is developing a portfolio of products with a wide range of beneficial healthcare applications in humans. Professor Godfroid’s research involved the collaboration of academic groups from Universite Catholique de Louvain, Facultes Universitaires Notre Dame de la Paix, Namur and Universite de Liege as well as the Universite de Neuchatel, Switzerland. Founded by an experienced group of seasoned healthcare and biotech executives with extensive experience in research, drug development, and commercialization, Bioxodes is based in Marche-en-Famenne, Belgium, with operations in the BioPark at Gosselies.

About the European Regional Development Fund (ERDF)

The ERDF aims to strengthen economic and social cohesion in the European Union by correcting imbalances between its regions http://ec.europa.eu/regional_policy/thefunds/regional/index_en.cfm

About RETECH

RETECH is the Walloon Region’s structural fund established to support research and technology companies in the region. http://recherche-technologie.wallonie.be/fr/menu/acteurs-institutionnels/service-public-de-wallonie-services-en-charge-de-la-recherche-et-des-technologies/departement-du-developpement-technologique/direction-des-projets-de-recherche/fonds-structurels-2007-2013/retech/retech.html

Mark Tidmarsh

mark@ala.com

ANDREW LLOYD & ASSOCIATES

http://www.ala.com

https://twitter.com/ALA_Group

Tel UK: +44 1273 675100

Tel France: +33 1 56 54 07 00

Tel US: +1 617 517 0146

INTERNATIONAL TECHNOLOGY MARKETS, STRATEGY & COMMUNICATION

Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

Bioxodes
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES